Description:
Reference #: 1665
The University of South Carolina is offering licensing opportunities for A novel formulation of nutraceutical compounds--PHMHP.
Background:
Natural compounds such as quercetin and emodin hold a great promise to be developed as therapeutic agents for various diseases such as cancer, cardiovascular disease, Alzheimer’s disease, inflammatory bowel diseases, and fibrotic diseases. However, they have not been approved by U.S. Food and Drug Administration (FDA) for any clinical applications. This is largely due to their low water solubility and low bioavailability.
Invention Description:
This innovation is a multiple step procedure to generate a novel formulation for nutraceutical compounds such emodin and quercetin. The formulation is designated Phospholipid Complex Hydroxypropyl Methylcellulose Hydrogel Pellets, PHMHP in short. This formulation is expected to significantly increase the oral bioavailability of nutraceutical compounds such as emodin and quercetin.
Potential Applications:
This novel formulation will improve the pharmacokinetic properties and increase the oral bioavailability of these nutraceutical compounds, therefore potentially enable these compounds to be approved by FDA as therapeutic drugs.
Advantages and Benefits:
This novel formulation will extend the time that the nutraceutical compounds stay in the GI tract where they can be absolved slowly but completely over time. In this way, the bioavailability will be increased, therapeutic efficacy will be improved, while the toxicity will be reduced, when patients take the formulated nutraceutical compounds.